STATE COLLEGE, Pa., March 8 /PRNewswire-FirstCall/ -- Chiral Quest, Inc. (BULLETIN BOARD: CQST) today announced the appointment of Strem Chemicals, Inc. as a distributor for several of its proprietary chiral ligand products through Strem's marketing and distribution channels. Chiral Quest ligands covered under this agreement include Binaphane, C3-TunePhos, TangPhos and Binapine.
Strem Chemicals, Inc., established in 1964, is a privately held company that manufactures and markets specialty chemicals of high purity. Its clients include academic, industrial and government R&D laboratories, as well as commercial-scale businesses in the pharmaceutical, microelectronic and chemical/petrochemical industries.
"Our relationship with Strem Chemicals will significantly enhance the availability of our unique chiral products," said Chiral Quest CEO and President Dr. Alan D. Roth. "Research scientists will benefit from the ease of order and rapid availability of our novel ligands through Strem and we are pleased to have them as a distribution partner."
"Strem Chemicals strives to provide our clients with the best available products for their research needs," said Dr. Ephraim S. Honig, Vice President of Strem. "We feel that Chiral Quest's are among the most innovative and unique chiral chemistry technologies available today, and we are happy to be able to provide them to our clients."
About Chiral Quest
Chiral Quest is a research-based life sciences chemistry company that provides chiral products, technology and services to the pharmaceutical and fine chemical industries. The Company develops chemical catalysts and other products used in the synthesis of desired isomers of chiral molecules. For more information, visit http://www.chiralquest.com/.
This press release contains forward-looking statements that involve risks and uncertainties that could cause Chiral Quest's actual results and experience to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Chiral Quest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Chiral Quest assumes no obligation and does not intend to update these forward-looking statements.
Chiral Quest, Inc.
CONTACT: Alan D. Roth, Ph.D., of Chiral Quest, Inc., +1-814-234-5054; orEphraim Honig, Ph.D., M.B.A., of Strem Chemicals, Inc., +1-978-462-3191; orInvestors, Ritu Baral of The Trout Group, +1-212-477-9007 ext. 25